774234-25-2

Usage

Uses

Used in Pharmaceutical Synthesis:
1-Boc-3-iodopyrrolidine is used as a key intermediate for the synthesis of various pharmaceutical compounds due to its ability to undergo nucleophilic substitution and subsequent functionalization after the removal of the Boc group.
Used in Agrochemical Production:
In the agrochemical industry, 1-Boc-3-iodopyrrolidine is utilized as a building block for the development of new agrochemicals, leveraging its reactivity and synthetic accessibility to create effective and targeted products.
Used in the Synthesis of Fine Chemicals:
1-Boc-3-iodopyrrolidine is employed as a versatile intermediate in the production of fine chemicals, where its unique structural features and synthetic flexibility are harnessed to create high-value specialty products.
Used in Organic Synthesis Research:
As a model compound in organic synthesis research, 1-Boc-3-iodopyrrolidine is used to explore new reaction pathways, develop innovative synthetic methods, and understand the fundamental principles of chemical reactivity and selectivity.

Upstream product

• 122684-33-7 methyl 1-tert-butoxycarbonyl-3-pyrrolidinecarboxylate 
• 3240-34-4 [bis(acetoxy)iodo]benzene 
• 72925-16-7 1-boc-pyrrolidine-3-carboxylic acid 
• 109431-87-0 (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate 
• 103057-44-9 N-(tert-butoxycarbonyl)-3-hydroxypyrrolidine 
• 17012-21-4 1-benzylpyrrolidine-3-carboxylic acid methyl ester 
• 51535-00-3 methyl 1-benzyl-5-oxo-3-pyrrolidinecarboxylate 

Downstream Products

• 1263285-96-6 tert-butyl 3-(4-fluorophenyl)pyrrolidine-1-carboxylate 
• 147410-43-3 tert-butyl 3-phenylpyrrolidine-1-carboxylate 
• 874218-24-3 tert-butyl 3-(pyridin-3-yl)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

Copper-Catalyzed Cross-Coupling between Alkyl (Pseudo)halides and Bicyclopentyl Grignard Reagents

The development of a copper-catalyzed cross-coupling between primary and secondary (pseudo)halides and bicyclopentyl Grignard reagents is reported. Highly strained bicyclopentanes can be cross-coupled with a large panel of primary alkyl mesylates and secondary alkyl iodides. The catalytic system is simple and cheap, and the reaction is general and chemoselective.

Introduction of Cyclopropyl and Cyclobutyl Ring on Alkyl Iodides through Cobalt-Catalyzed Cross-Coupling

A cobalt-catalyzed cross-coupling between alkyl iodides and cyclopropyl, cyclobutyl, and alkenyl Grignard reagents is disclosed. The reaction allows the introduction of strained rings on a large panel of primary and secondary alkyl iodides. The catalytic system is simple and nonexpensive, and the reaction is general, chemoselective, and diastereoconvergent. The alkene resulting from the cross-coupling can be transformed to substituted cyclopropanes using a Simmons-Smith reaction. The formation of radical intermediates during the coupling is hypothesized.

[1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

Iron- and cobalt-catalyzed arylation of azetidines, pyrrolidines, and piperidines with grignard reagents

Iron- and cobalt-catalyzed cross-couplings between iodo-azetidines, -pyrrolidines, -piperidines, and Grignard reagents are disclosed. The reaction is efficient, cheap, chemoselective and tolerates a large variety of (hetero)aryl Grignard reagents.

ALKENYL NAPHTHYLACETIC ACIDS

The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Ni-catalyzed cascade cyclization-kumada alkyl-alkyl cross-coupling

Suggesting novel disconnections: A powerful Ni-catalyzed cascade reaction involving cyclization followed by cross-coupling allows the formation of up to three alkyl-alkyl bonds in a single operation by using alkene-containing alkyl iodides and Grignard reagents (see scheme; acac=acetylacetonate; TMEDA=N,N′,N′-tetramethyl ethylenediamine). Mechanistic experimental and computational studies suggest a NiI-NiII-Ni III catalytic cycle and the intermediacy of radicals. Copyright

Heterocyclic antiviral compounds

Compounds having the formula I wherein R1, R2, R3, R4, R5 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV

Synthesis of functionalized nitrogen heterocycles by radical decarboxylation of β- and γ-amino acids

Iodinated or oxygenated nitrogen heterocycles are obtained by radical decarboxylation of β- and γ-amino acids. This mild, versatile reaction is applied to the synthesis of bioactive products, such as 4-arylpiperidines, hydroxylated piperidines, and new antifungal agents.

Synthesis of functionalized nitrogen heterocycles from β- And γ-amino acids by radical decarboxylation

The radical decarboxylation of β- and γ-amino acids on treatment with PhI(OAc)2a-I2 is a mild and efficient methodology to synthesize halogenated or oxygenated nitrogen heterocycles. The reaction was applied to the synthesis of bioactive products, such as opioid analogues, iminosugars and new antifungic agents.